Northwest Biotherapeutics, Inc.
corporate_fare Company Profile
Northwest Biotherapeutics, Inc. (OTC:NWBO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for NWBO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for NWBO spans 10-Q, 8-K, 424B5, 10-K.
Recent high-impact activity:
- NW Bio Q3 Loss $28.8M, Cash Down to $725K, Going Concern Reaffirmed
- NW Bio Raises $5.5M in Streeterville Debt With 10% OID and 8% Interest
- NW Bio Partners with UK NHS Blood and Transplant to Scale DCVax-L Production
- NW Bio's Q2 Loss, Going Concern Warning, and Heavy Dilution
- NW Bio Lands $4.9M Convertible Note and $50M Standby Equity Facility with Yorkville
Financial Snapshot
Short Interest & Short Volume
7.78 days to coverFINRA reported short interest of 69,421,915 shares in NWBO as of the October 30, 2026 settlement, a 5.1% decrease from the prior period — about 7.8 days to cover at its recent average daily volume. On November 20, 2026, 57.2% of NWBO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for NWBO, detected from its recent SEC filings · based on capital-structure filings through 2026-07-31.
$4.9M Convertible Note with Yorkville · 40.3M Shares Registered for Conversion & Warrants
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →